Industry
Biotechnology
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Loading...
Open
6.78
Mkt cap
302M
Volume
833K
High
6.83
P/E Ratio
-1.25
52-wk high
11.35
Low
5.99
Div yield
N/A
52-wk low
3.73
Portfolio Pulse from
November 08, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
September 20, 2024 | 4:25 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 3:54 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 10:28 am
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 5:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.